Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in American men, with an estimated 186,320 new cases diagnosed and 28,660 prostate cancer deaths expected in the US in 2008. 1 With the use of prostate-specific antigen (PSA)-based screening, the number of prostate biopsies performed to diagnose prostate cancer has risen sharply over the past two decades, with a majority of those biopsies being negative. 2 Conversely, the falsenegative rate of standard transrectal ultrasound (TRUS)-guided prostate biopsy is significant, approaching 30-40%. 3 Additionally, the clinical significance of low-volume, low-grade prostate cancer detected on needle biopsy is unclear. The controversy regarding the potential overtreatment of 'clinically insignificant' prostate tumours is balanced by the infrequent but concerning finding of higher volume, highergrade tumours recognised on final surgical pathology after radical prostatectomy. Improved diagnostic methods are necessary to more accurately detect prostate cancer while minimising unnecessary biopsies. Several new diagnostic imaging modalities being explored to improve the accurate diagnosis of prostate cancer are presented here.
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Transrectal Ultrasound

Contrast Enhancement
Use of ultrasound contrast agents to improve biopsy targeting accuracy and cancer detection of TRUS-guided needle biopsy of the prostate has been an ongoing research interest at our institution and others. Prostate cancer, like many other neoplasms, demonstrates neovascularity and increased microvessel density, with important prognostic implications. 4 Based on the pathological finding of increased vascularity in prostate cancer, there has been great interest in using Doppler ultrasound to increase sensitivity and specificity for the detection of prostate cancer. biopsy cannot be eliminated, as the sensitivity of Doppler imaging is not sufficient to detect many of the lesions found by systematic biopsy. [12] [13] [14] Halpern et al. at Jefferson published a study analysing the use of intravenous sonographic contrast agents injected during TRUS analysis of the prostate with colour and power Doppler. 15 The intravenous contrast agent utilises microbubbles, which enhance the ultrasound identification of microvascular flow anomalies associated with prostate cancer. In the trial by Halpern and colleagues, an intermittent harmonic greyscale imaging technique was used. This method provides an inter-scan delay that allows the contrast media to accumulate in the microvascular spaces before the microbubbles are destroyed by the ultrasound wave. 15 A total of 301 men had microbubble contrast agents infused during TRUS, and areas of increased vascularity identified with colour or power Doppler were targeted for needle biopsy. Additional modified sextant biopsies were taken after the targeted biopsies, and the cancer detection rate of each biopsy strategy was analysed. Cancer was detected in 35% of men; targeted biopsies had a cancer detection rate of 15.5% compared with a cancer detection rate in modified sextant biopsies of 10.4%. In men in whom cancer was detected, targeted biopsies were twice as likely to be positive as modified sextant biopsies 
Diagnostic Imaging Approaches to Prostate Cancer
These results are comparable to those from a similar collaborative study from Austria and Philadelphia. Pelzer et al. published a study examining the utility of adding prostate biopsies targeted to lesions identified with ultrasound contrast agents to a systematic biopsy approach. 16 Three hundred and eighty patients with a serum PSA level between 4 and 10ng/ml received an intravenous ultrasound contrast microbubble agent, and contrast-enhanced colour Doppler (CECD) targeted biopsies were performed in areas of peripheral-zone hypervascularity. Additional standard systematic 10-core biopsies were then taken by another blinded examiner. The overall percentage of patients with cancer was 37.6% (143/380). The positive biopsy rates were comparable in the CECD biopsies and systematic biopsies (27.4 and 27.6%, respectively).
The combination of CECD biopsies with standard 10-core systematic biopsies increased the overall positive biopsy rate to 37.6%, with the percentage of positive individual positive cores significantly higher in the CECD-targeted biopsies compared with standard systematic biopsies (32.6 and 17.9%, respectively; p<0.01).
Elastography
Cancerous prostate tissue can be firm to palpation, with limited elastisticity or compressibility. Elastography of the prostate using TRUS uses this lack of compressibility as a targeting strategy. In a pilot study 
Magnetic Resonance Imaging
Dynamic Contrast-enhanced Magnetic Resonance Imaging
The technique of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is designed to take advantage of the increased vascularity that occurs in and around malignant tumours. The study is DCE-MRI has also been studied as an alternative to biopsy for the diagnosis of prostate cancer in the setting of elevated PSA in a Japanese population. Hara et al. 19 investigated men with an elevated serum PSA level (defined as >2.5ng/ml) and compared DCE-MRI as a detection modality versus 14-core biopsy. DCE-MRI in this study detected 92.9% of clinically significant prostate cancers with a specificity of 96.3%. For men with PSA <10ng/ml, the accuracy was 80.5%. With further improvements in technology and software, this modality holds promise for improved cancer detection and the ability to perform more selective biopsies in men with elevated PSA.
Magnetic Resonance Spectroscopic Imaging
MRSI is an imaging technique that provides a metabolic analysis of prostate tissue. The utility of this technique is derived from the differences in metabolic profile that exist between normal and malignant prostate tissue. Specifically, areas of prostatic malignancy tend to exhibit higher relative concentrations of choline and reduced levels of citrate.
Zakian et al. investigated whether these differences could be used to predict prostate cancer aggressiveness, i.e. Gleason score, in a study of 94 men imaged prior to undergoing radical prostatectomy. 20 Postoperative whole-mount histological analysis was compared with preoperative MRSI. Transrectal biopsy correctly predicted Gleason score in 64.2% of the patients. In the 94 patients evaluated, 239 peripheral-zone lesions were identified. MRSI correctly identified 135 of these lesions and performed best in identifying higher-grade lesions (sensitivity 44.4% for Gleason score 3+3 versus sensitivity 89.5% for Gleason score 4+4). The improved performance in higher-grade lesions was due to the positive correlation between increasing choline plus creatine to citrate ratio (Ch plus Cr to Cit) and increasing tumour aggressiveness. In Gleason score 3+3 lesions, tumour size was a significant factor in MRSI tumour detection (average largest diameter for tumours not detected was 7.9±4.9mm compared with 11.6±6.8mm for tumours that were detected; p<0.001). From the same group, a recent study examined preoperative MRSI in comparison with whole-mount prostatectomy specimens to predict clinically insignificant prostate cancer tumours. 21 Compared with standard pre-operative clinical parameters and endorectal MRI, the use of MRSI more accurately predicted which patients had small-volume, low-grade tumours that were likely to be Imaging and Radiotherapy clinically insignificant. This approach could be used to counsel men electing for deferred therapy or 'watchful waiting'.
Cancer Detection with Previous Negative Biopsies
Another setting in which MRSI has shown promise is in patients with elevated PSA and previously negative biopsies. In a group of 42 men at high risk of prostate cancer (mean PSA 12ng/ml; mean number of prior negative biopsies 2.04), Amsellem-Ouazana et al. utilised pre-biopsy combined MRI/MRSI to identify areas suspicious for cancer. 22 
Positron Emission Tomography
Several studies have examined the utility of positron emission tomography (PET) for prostate biopsy and initial staging of prostate cancer. A Hungarian study by Toth et al. examined the use of carbon-11 (C-11) methionine in patients with persistently elevated PSA and previous negative biopsies. 24 A total of 20 patients were enrolled, with a mean PSA of 9.36ng/ml (range: Therefore, these studies suggest that PET scanning may help to localise suspicious areas within the prostate for both targeting on repeat biopsy to improve the detection of prostate cancer and for more accurately assessing the laterality of tumour prior to radical prostatectomy. With further enhancements, the ability to identify those men with aggressive and potentially life-threatening cancers will improve. ■
Conclusion
